Alcon Charts a New Course: PowerVision Exit, RxSight Pact, and a Tariff Windfall

Strong 7% growth and raised guidance, but the real story is a strategic pivot on adjustable IOLs and a $60M refund to reinvest.

ALC · Earnings Call · 2026-08-11

A Quarter of Strong Execution

Alcon delivered a solid second quarter, with sales up 7% to $2.8 billion, broad-based across Surgical and Vision Care. Equipment sales jumped 25% on the back of the UNITY VCS launch, and management highlighted "strong customer engagement and a healthy sales funnel" with “clear visibility into our second half placements” — David Endicott, Chief Executive Officer · 2026-08-11. The PanOptix Pro rollout continues to exceed expectations—nearly all PanOptix accounts have converted, with the platform now representing roughly 90% of PanOptix implants. On the Vision Care side, the order book remains robust, and TRYPTYR is already capturing ~5% market share less than a year post-launch. Equally important, Alcon raised its full-year guidance: core operating margin expansion is now expected at 90–190 basis points (up from 70–170), and constant-currency core EPS growth is guided to 12–15%. The company also confirmed an expected ~$60 million tariff refund from the U.S. government in Q3, of which roughly two-thirds will be reinvested in growth initiatives.

Strategic Pivot: From PowerVision to RxSight

Perhaps the most consequential news is the discontinuation of the PowerVision accommodative IOL program. David Endicott explained on the call:

This data demonstrated persistent unpredictable shifts in postoperative distance vision in a subset of patients that remain unresolved after multiple developmental efforts. As a result, the programs did not meet our standards for visual performance and patient outcomes.
David Endicott, Chief Executive Officer · 2026-08-11

This is a clear acknowledgment that the hard problem of an accommodative lens remains unsolved. The company is now pivoting to a collaboration with RxSight to develop a next-generation adjustable lens, a strategic shift from internal R&D to partnership. During Q&A, Endicott clarified that the long-term goal is still an accommodating/tunable lens, but PowerVision's failure has pushed that horizon further out: “We still think that adjustable accommodating is the best long-term answer. We just couldn't get there with this particular technology.” — David Endicott, Chief Executive Officer · 2026-08-11 This is a notable change from prior quarters. On the Q1 2026 call, the company had indicated data from the PowerVision trial would be available "somewhere between here and the next call" (prior transcript, component 79387157999900483). That data has now arrived—and it was negative enough to terminate the program. In contrast, the RxSight collaboration is a fresh initiative, breaking from the prior stance of primarily internal development. Management framed it as an intermediate step: “RxSight really is an idea about how do we take a step forward in tunability with an optic that we already have or one that we could design for it.” — David Endicott, Chief Executive Officer · 2026-08-11

Tariff Refund and Raised Guidance

The tariff refund is a new, concrete catalyst. CFO Tim Stonesifer noted that the $60 million refund will be reinvested, with roughly two-thirds going back into the business. He detailed, “We're going to double down in a couple of the areas that we think that there's more opportunity. We're also going to look at other OTC products.” — Timothy Stonesifer, Chief Financial Officer · 2026-08-11 This reflects increased conviction after a strong first half, and it explains the higher operating margin guidance even as SG&A spending is planned to hold steady as a percentage of sales in H2. The company is also navigating a slower U.S. cataract market—flat volumes in Q2—but AT-IOL penetration rose 180 bps in the U.S. and 110 bps globally, which is a value tailwind. Management noted that 1 point of penetration is worth ~$15 million per quarter versus ~$10 million for 1 point of market growth. This helps offset the volume softness and supports the raised EPS outlook. Looking ahead, the pipeline remains active: Vivity Pro is expected to launch with KOLs late this year, TruPlus has CE Mark, and the first microscope (UNITY M) was sold. The company also teased a new eye whitener for next year. The strategic pivot on adjustable IOLs, combined with a strong base business and a tariff windfall, positions Alcon to maintain its leadership—even as it concedes that the ultimate accommodative lens remains elusive.